GlassScriptPhysician profile
David Michael Dyer
NPI 1598155947
$1,787.01
in general payments reported to CMS, 2019-2025
20 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $361 · 2022: $271 · 2023: $430 · 2024: $426 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,154.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $514.75 | 2021-2025 | Briviact, Nayzilam, Fintepla |
| Pfizer INC. | $188.86 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $164.32 | 2021-2024 | Xarelto |
| Gilead Sciences, INC. | $127.38 | 2021-2025 | Veklury |
| Paratek Pharmaceuticals, INC. | $125.54 | 2021-2025 | Nuzyra |
| Melinta Therapeutics, LLC | $105.80 | 2021-2023 | Vabomere, Kimyrsa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.66 | 2021-2023 | Jardiance, Stiolto Respimat |
| La Jolla Pharmaceutical Company | $74.89 | 2023-2024 | Xerava |
| E.R. Squibb & Sons, L.L.C. | $72.85 | 2023-2024 | Camzyos, Eliquis |
| Lemaitre Vascular, INC. | $58.56 | 2021 | |
| Novo Nordisk INC | $55.23 | 2025 | Ozempic, Rybelsus |
| Boston Scientific Corporation | $35.06 | 2024-2025 | Watchman Flx |
| Merck Sharp & Dohme LLC | $28.59 | 2023 | Zerbaxa, Recarbrio, Dificid |
| Pyros Pharmaceuticals, INC. | $25.59 | 2024 | Vigpoder |
| Tactile Systems Technology INC | $22.83 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $20.75 | 2024 | |
| Novartis Pharmaceuticals Corporation | $19.84 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $17.13 | 2023 | Arcalyst |
| Medtronic, INC. | $16.38 | 2024 | Venaseal |
| Alnylam Pharmaceuticals INC. | $15.00 | 2024 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.